M. Chmielewski and M. Kuch, “Why do the latest guidelines on the treatment of hypertension (PTNT 2015) indicate that telmisartan, as an exception among ARBs, should be the drug of choice in patients with hypertension and multiple cardiovascular risk factors”, J EBM, vol. 9, no. 1(30), pp. 30-31, Mar. 2016.